May 21, 2025

Medical Oddities: Fingernail Selfies Spot Anemia

Tea, tech, TikTok & toxins: surprising health twists hiding in phones, roads, and skin care.

Conexiant

May 21, 2025

Birth Control Pills Triple Stroke Risk?

New SECRETO study reveals combined oral contraceptives increase cryptogenic ischemic stroke risk threefold in women aged 18 to 49, independent of other known risk factors.

Conexiant

May 20, 2025

ICU Sedation Economics: A $1 Difference

Study finds dexmedetomidine, clonidine, and propofol have comparable cost-effectiveness for critically ill patients on mechanical ventilation.

Conexiant

May 15, 2025

Medical Oddities: Mini Lab-Grown Ovaries Go Natural

Mini ovaries steal the show—plus heart cell choreography, Brussels sprout bias, and prenatal tea perks.

Conexiant

May 01, 2025

Fas Inhibition Shows Neuroprotective Benefit for GA

An investigational Fas inhibitor demonstrated encouraging results in patients with geographic atrophy (GA) in a phase 1b clinical trial. In the study, eyes treated with ONL1204 (ONL Therapeutics) showed reductions in GA lesion growth at 6 months of up to 50% compared to sham-treated eyes after 2 injections spaced 3 months apart, and a 42% reduction in lesion growth compared to fellow untreated eyes after a single injection.

Retinal Physician

May 01, 2025

FDA Shares Insights on Treatment Approvals, Clinical Trial Design

Dr. William Boyd, head of the FDA’s ophthalmology division, discussed his agency and answered questions related to retinal trials at RWC 2025.

Retinal Physician

May 01, 2025

Current Pipeline for Noninfectious Uveitis

Dilraj Grewal, MD, an associate professor of ophthalmology at the Duke Eye Center in Durham, North Carolina, and associate director of the Duke Reading Center, reviewed investigational therapies currently in late-stage clinical trials that may soon expand the treatment armamentarium for noninfectious uveitis during the Retina World Congress in Fort Lauderdale, Florida.

Retinal Physician

May 01, 2025

PRISM Trial Update Presented at RWC

Mark Barakat, MD, provided an update on the PRISM clinical trial for 4D-150 (4DMT) for wet AMD at the Retina World Congress meeting in Fort Lauderdale.

Retinal Physician

May 01, 2025

Reducing the Risk of Radiation Retinopathy

Radiation retinopathy remains the leading cause of vision loss following plaque brachytherapy for choroidal melanoma. However, emerging research is changing the ways that ophthalmologists manage, or potentially prevent, this complication.

Retinal Physician